"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs" by Vibeke Strand

Article

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

RMD Open (2019)

Vibeke Strand, Stanford University
Kurt de Vlam, Katholieke Universiteit Leuven
Jose A Covarrubias-Cobos, Unidad Reumatologica Las Americas S.C.P
Philip J Mease, University of Washington
Dafna D Gladman, Toronto Western Hospital
Daniela Graham, Pfizer
Cunshan Wang, Pfizer
Joseph C Cappelleri, Pfizer
Thijs Hendrikx, Pfizer
Ming-Ann Hsu, Pfizer

Link

Disciplines

Publication Date

January 1, 2019

DOI

10.1136/rmdopen-2018-000806

Citation Information

Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip J Mease, et al.. "Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs" RMD Open Vol. 5 Iss. 1 (2019)
Available at: http://works.bepress.com/philip-mease/315/